The company aims to focus on moving projects to revenue-generating development within their ECO Innovation Lab. They prioritize partnerships with major siRNA drug developers and emphasize quality over quantity. Enzymatic production offers quality and environmental benefits, with significant revenue potential as mRNA production scales up.